M
Mohammad M. Sajadi
Researcher at University of Maryland, Baltimore
Publications - 97
Citations - 3287
Mohammad M. Sajadi is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Antibody & Medicine. The author has an hindex of 28, co-authored 81 publications receiving 2473 citations. Previous affiliations of Mohammad M. Sajadi include Global Virus Network & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19).
Mohammad M. Sajadi,Mohammad M. Sajadi,Parham Habibzadeh,Augustin Vintzileos,Shervin Shokouhi,Fernando Miralles-Wilhelm,Fernando Miralles-Wilhelm,Anthony Amoroso,Anthony Amoroso +8 more
TL;DR: In this cohort study of 50 cities with and without coronavirus disease 2019, areas with substantial community transmission of COVID-19 had distribution roughly along the 30° N to 50° N latitude corridor with consistently similar weather patterns, consisting of mean temperatures of 5 to 11 °C combined with low specific and absolute humidity.
Journal ArticleDOI
Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19
Mohammad M. Sajadi,Parham Habibzadeh,Augustin Vintzileos,Shervin Shokouhi,Fernando Miralles-Wilhelm,Fernando Miralles-Wilhelm,Anthony Amoroso +6 more
TL;DR: Using weather modeling, it may be possible to predict the regions most likely to be at higher risk of significant community spread of COVID-19 in the upcoming weeks, allowing for concentration of public health efforts on surveillance and containment.
Journal ArticleDOI
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
Saman Saadat,Zahra Rikhtegaran Tehrani,James Logue,Michelle Newman,Matthew B. Frieman,Anthony D. Harris,Mohammad M. Sajadi +6 more
TL;DR: In this paper, the titers of binding and neutralizing antibodies after a single mRNA coronavirus vaccine dose in health care workers previously infected with SARS-CoV-2 were compared.
Journal ArticleDOI
Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
Anu Osinusi,Anu Osinusi,Kerry Townsend,Anita Kohli,Anita Kohli,Amy Nelson,Amy Nelson,Cassie Seamon,Eric G. Meissner,Eric G. Meissner,Dimitra Bon,Rachel Silk,Rachel Silk,Chloe Gross,Chloe Gross,Angie Price,Angie Price,Mohammad M. Sajadi,Sreetha Sidharthan,Zayani Sims,Eva Herrmann,John F. Hogan,Gebeyehu Teferi,Rohit Talwani,Michael A. Proschan,Veronica Jenkins,David E. Kleiner,Brad Wood,G. Mani Subramanian,Phillip S. Pang,John G. McHutchison,Michael A. Polis,Anthony S. Fauci,Henry Masur,Shyam Kottilil,Shyam Kottilil +35 more
TL;DR: In this open-label, uncontrolled, pilot study enrolling patients co-infected with HCV genotype 1 and HIV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated with high rates of SVR after treatment completion.
Journal ArticleDOI
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.
Kathryn M. Hastie,Haoyang Li,Daniel Bedinger,Sharon L. Schendel,S. Moses Dennison,Kan Li,Vamseedhar Rayaprolu,Xiaoying Yu,Colin Mann,Michelle Zandonatti,Ruben Diaz Avalos,Dawid Zyla,Tierra Buck,Sean Hui,Kelly Shaffer,Chitra Hariharan,Jieyun Yin,Eduardo Olmedillas,Adrian Enriquez,Diptiben V. Parekh,Milite Abraha,Elizabeth Feeney,Gillian Q. Horn,CoVIC-DB team,Yoann Aldon,Hanif Ali,Sanja Aracic,Ronald R. Cobb,Ross S. Federman,Joseph M. Fernandez,Jacob Glanville,Robin Green,Gevorg Grigoryan,Ana G. Lujan Hernandez,David D. Ho,Kuan-Ying A. Huang,John Ingraham,Weidong Jiang,Paul Kellam,Cheolmin Kim,Minsoo Kim,Hyeong Mi Kim,Chao Kong,Shelly J. Krebs,Fei Lan,Guojun Lang,Sooyoung Lee,Cheuk Lun Leung,Junli Liu,Yanan Lu,Anna J. MacCamy,Andrew T. McGuire,Anne L. Palser,Terence H. Rabbitts,Zahra Rikhtegaran Tehrani,Mohammad M. Sajadi,Rogier W. Sanders,Aaron K. Sato,Liang Schweizer,Jimin Seo,Bingqing Shen,Jonne L. Snitselaar,Leonidas Stamatatos,Yongcong Tan,Milan T. Tomic,Marit J. van Gils,Sawsan Youssef,Jian Yu,Tom Z. Yuan,Qian Zhang,Bjoern Peters,Georgia D. Tomaras,Timothy C. Germann,Erica Ollmann Saphire +73 more
TL;DR: Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as discussed by the authors.